The estimated Net Worth of Ann Calby Miller is at least $1 Milion dollars as of 15 May 2024. Ann Miller owns over 2,166 units of Puma Biotechnology Inc stock worth over $19,275 and over the last 6 years he sold PBYI stock worth over $147,150. In addition, he makes $834,573 as Independent Director at Puma Biotechnology Inc.
Sign up
Ann Miller PBYI stock SEC Form 4 insiders trading
Ann has made over 9 trades of the Puma Biotechnology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,166 units of PBYI stock worth $5,415 on 15 May 2024.
The largest trade he's ever made was exercising 19,000 units of Puma Biotechnology Inc stock on 15 May 2023 worth over $47,500. On average, Ann trades about 4,532 units every 84 days since 2019. As of 15 May 2024 he still owns at least 7,710 units of Puma Biotechnology Inc stock.
You can see the complete history of Ann Miller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ann Miller biography
Dr. Ann Calby Miller M.D. serves as Independent Director of the Company. Dr. Miller has been a director since November 2019. Since March 2019, Dr. Miller has served as a member of the board of directors of Inovio Pharmaceuticals, Inc., a publicly held biotechnology company focused on the discovery, development, and commercialization of its synthetic DNA technology targeted against cancers and infectious diseases. Prior to that, Dr. Miller worked at Sanofi S.A., a global pharmaceutical company based in France, from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr. Miller served as Senior Vice President of Pharmaceutical Services and Senior Vice President of the Primary Care and Specialty Business unit at Eisai Co., Ltd, a global research and development based pharmaceutical company based in Japan. Dr. Miller previously served in management roles in global marketing at Amgen Inc. (“Amgen”) over a period of six years and in positions of increasing responsibility at Merck & Co., Inc. over a period of 16 years. Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in chemistry with honors from Duke University. Dr. Miller was nominated to serve as a director because of her broad commercial background in the biopharmaceutical industry and her clinical training and experience.
What is the salary of Ann Miller?
As the Independent Director of Puma Biotechnology Inc, the total compensation of Ann Miller at Puma Biotechnology Inc is $834,573. There are 7 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
How old is Ann Miller?
Ann Miller is 62, he's been the Independent Director of Puma Biotechnology Inc since 2019. There are 3 older and 11 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
What's Ann Miller's mailing address?
Ann's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE SUITE 110, , PLYMOUTH MEETING, PA, 19462.
Insiders trading at Puma Biotechnology Inc
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo a Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
What does Puma Biotechnology Inc do?
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
What does Puma Biotechnology Inc's logo look like?
Complete history of Ann Miller stock trades at Inovio Pharmaceuticals Inc, Puma Biotechnology Inc a Allena Pharmaceuticals Inc
Puma Biotechnology Inc executives and stock owners
Puma Biotechnology Inc executives and other stock owners filed with the SEC include:
-
Alan H. Auerbach,
Founder, Chairman, Pres, CEO & Sec. -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alan Auerbach,
Chairman of the Board, President, Chief Executive Officer -
Douglas Hunt B.Sc., FRAPS,
Sr. VP of Regulatory Affairs, Medical Writing & Project Management -
Maximo F. Nougues,
CFO & Principal Accounting Officer -
Douglas Hunt,
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management -
Richard Bryce,
Chief Medical and Scientific Officer -
Ann Miller,
Independent Director -
Dr. Richard P. Bryce,
Chief Medical & Scientific Officer -
Maximo Nougues,
Chief Financial Officer -
Hugh O Dowd,
Independent Director -
Jay Moyes,
Lead Independent Director -
Troy Wilson,
Independent Director -
Adrian Senderowicz,
Independent Director -
Michael Miller,
Independent Director -
Mariann Ohanesian,
IR Contact Officer -
Brian Stuglik,
Director -
Dr. Alvin F. Wong,
Chief Scientific Officer -
Charon Spencer Sr.,
VP of HR -
Steven Lo,
Chief Commercial Officer -
Capital Partners Gp, L.L.C....,
-
Robert Charnas,
-
Richard Benton Phillips,
SEE REMARKS -
Charles R Eyler,
SEE REMARKS -
Frank Zavrl,
Director -
Thomas Malley,
Director -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alvin F Wong,
Chief Scientific Officer -
Allison Dorval,
Director -
Alessandra Cesano,
Director